IMMUNOGLOBULIN G4, ANTI-(MULTIPLE SCLEROSIS-ASSOCIATED RETROVIRUS VIRAL ENVELOPE PROTEIN) (HUMAN-MUS MUSCULUS MONOCLONAL GNBAC1 HEAVY CHAIN), DISULFIDE WITH HUMAN-MUS MUSCULUS MONOCLONAL GNBAC1 .KAPPA.-CHAIN, DIMER
Post-COVID-19 Syndrome
GeNeuro SAmonoclonal_antibodyPhase 2Active
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 95/ 100
Competitive context
31 Active assets in the Post-COVID-19 Syndrome cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Immulina Tm University of Mississippi Medical Center | Phase 3 | BB |
MELATONIN Duke University | Phase 2 | B |
Rapamycin Icahn School of Medicine at Mount Sinai | Phase 3 | B |
Paxlovid Kanecia Obie Zimmerman | Phase 2 | B |
RITONAVIR Kanecia Obie Zimmerman | Phase 2 | B |
View all 31 →
Same molecule, other indications
IMMUNOGLOBULIN G4, ANTI-(MULTIPLE SCLEROSIS-ASSOCIATED RETROVIRUS VIRAL ENVELOPE PROTEIN) (HUMAN-MUS MUSCULUS MONOCLONAL GNBAC1 HEAVY CHAIN), DISULFIDE WITH HUMAN-MUS MUSCULUS MONOCLONAL GNBAC1 .KAPPA.-CHAIN, DIMER is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →